A5061409844- Mosquito-borne diseases and control
- Virus-based gene therapy research
- HIV Research and Treatment
- Virology and Viral Diseases
- Viral Infections and Vectors
- Immunotherapy and Immune Responses
- Herpesvirus Infections and Treatments
- Viral Infections and Outbreaks Research
- Animal Virus Infections Studies
- Viral gastroenteritis research and epidemiology
- Influenza Virus Research Studies
- Immune Cell Function and Interaction
- Malaria Research and Control
- Monoclonal and Polyclonal Antibodies Research
- Bacteriophages and microbial interactions
- vaccines and immunoinformatics approaches
- Viral Infections and Immunology Research
- Toxoplasma gondii Research Studies
- Hepatitis B Virus Studies
Emergent BioSolutions (United States)
2020-2023
PaxVax (United States)
2012-2019
PAX Scientific (United States)
2012-2019
Pfizer (United States)
2012
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes epidemics of acute and chronic musculoskeletal disease. Here, we analyzed the human B cell response to CHIKV-like particle–adjuvanted vaccine (PXVX0317) from samples obtained phase 2 clinical trial in humans (NCT03483961). Immunization with PXVX0317 induced high levels neutralizing antibody serum against CHIKV circulating antigen–specific cells up 6 months after immunization. Monoclonal antibodies (mAbs) generated...
Background Influenza virus remains a significant health and social concern in part because of newly emerging strains, such as avian H5N1 virus. We have developed prototype vaccine using recombinant, replication-competent Adenovirus serotype 4 (Ad4) vector, derived from the U.S. military Ad4 strain, to express hemagglutinin (HA) gene A/Vietnam/1194/2004 influenza (Ad4-H5-Vtn). Our hypothesis is that mucosally-delivered replicating Ad4-H5-Vtn recombinant vector will be safe induce protective...
Zika virus (ZIKV) poses a serious public health threat due to its association with birth defects in developing fetuses and Guillain-Barré Syndrome adults. We are ZIKV vaccine based on virus-like particles (VLPs) generated transiently transfected HEK293 cells. The genetic construct consists of the prM envelope structural protein genes placed downstream from heterologous signal sequence. To better understand humoral responses correlates protection (CoP) induced by VLP vaccine, we evaluated...
We created and tested multi-epitope DNA or protein vaccines with TLR4 ligand emulsion adjuvant (gluco glucopyranosyl lipid in a stable [GLA-SE]) for their ability to protect against Toxoplasma gondii HLA transgenic mice. Our constructs each included 5 of our best down-selected CD8+ T cell–eliciting epitopes, universal CD4+ helper lymphocyte epitope (PADRE), secretory signal, all arranged optimal MHC-I presentation. Their capacity elicit immune protective responses was studied using...
Alphavirus infections are a global health threat, contributing to outbreaks of disease in many parts the world. Recent epidemics caused by CHIKV, an arthritogenic alphavirus, resulted more than 8.5 million cases as virus has spread into new geographic regions, including Western Hemisphere. CHIKV causes majority people infected, leading severe and debilitating arthritis. Despite severity disease, there no licensed therapeutics. Since attachment factors receptors determinants viral tropism...
Arenaviruses are the causative pathogens of severe hemorrhagic fever and aseptic meningitis in humans, for which no licensed vaccines currently available. Pathogen heterogeneity within Arenaviridae family poses a significant challenge vaccine development. The main hypothesis we tested present study was whether it is possible to design universal strategy capable inducing simultaneous HLA-restricted CD8+ T cell responses against 7 pathogenic arenaviruses (including lymphocytic...
Background Zika virus (ZIKV), a mosquito-borne flavivirus, is re-emerging that constitutes public health threat due to its recent global spread, recurrent outbreaks, and infections are associated with neurological abnormalities in developing fetuses Guillain-Barré syndrome adults. To date, there no approved vaccines against ZIKV infection. Various preclinical clinical development programs currently ongoing an effort bring forward vaccine for ZIKV. Methodology/Principle findings We have...
Background There is a well-acknowledged need for an effective AIDS vaccine that protects against HIV-1 infection or limits in vivo viral replication. The objective of these studies to develop replication-competent, vector based on the adenovirus serotype 4 (Ad4) virus expressing envelope (Env) 1086 clade C glycoprotein. Ad4 recombinant vectors Env gp160 (Ad4Env160), gp140 (Ad4Env140), and gp120 (Ad4Env120) were evaluated. Methods generated with full deletion E3 region accommodate env gene...
HIV vaccine development is focused on designing immunogens and delivery methods that elicit protective immunity. We evaluated a combination of adenovirus (Ad) vectors expressing 1086.C (clade C) envelope glycoprotein (Env), SIV Gag p55, human pegivirus GBV-C E2 glycoprotein. compared replicating simian (SAd7) with nonreplicating (Ad4) adenovirus-vectored vaccines paired recombinant proteins in novel prime-boost regimen rhesus macaques, the goal eliciting immunity against SHIV challenge. In...
Designing immunogens and improving delivery methods eliciting protective immunity is a paramount goal of HIV vaccine development. A comparative challenge study was performed in rhesus macaques using clade C Envelope (Env) SIV Gag antigens. One group vaccinated co-immunization with DNA Env expression plasmids cloned from single timepoint trimeric gp140 glycoprotein one these clones (DNA+Protein). The other prime-boost regimen composed two replicating simian (SAd7) adenovirus-vectored vaccines...
Zika virus (ZIKV) is a mosquito-borne flavivirus with maternal infection associated preterm birth, congenital malformations, and fetal death, adult Guillain-Barré syndrome. Recent widespread endemic transmission of ZIKV the potential for future outbreaks necessitate development an effective vaccine. We developed vaccine candidate based on virus-like-particles (VLPs) generated following transfection mammalian HEK293T cells using plasmid encoding pre-membrane/membrane (prM/M) envelope (E)...
Background Our hypothesis is that the replicating Ad4 vector approach, may be best strategy for an effective HIV-1 vaccine due to advantages of demonstrated clinical safety and immunogenicity both backbone H5N1 influenza evaluated in Phase 1. Unlike other vectors, it can bioengineered express full-length Env gp160. More than 50% global infections are caused by clade C viruses therefore we initiated development Ad4-Env160 using sequence obtained from CHAVI.